| P2093 | author name string | J Dingemanse | |
| | B Wagner | |
| | A Korn | |
| | E Moritz | |
| P2860 | cites work | Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. | Q51627617 |
| | Biochemistry and pharmacology of moclobemide, a prototype RIMA | Q57382336 |
| | The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine | Q67919864 |
| | Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects | Q68002128 |
| | Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor | Q69956034 |
| | Tyramine pressor sensitivity changes during deprenyl treatment | Q69962076 |
| | Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase | Q71064705 |
| | The effect of monoamine oxidase inhibitors on 'first-pass' metabolism of tyramine in dog intestine | Q71350810 |
| | Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline | Q71721552 |
| | Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs | Q72242299 |
| | Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers | Q82884630 |
| | Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness | Q28187265 |
| | Biochemistry and pharmacology of moclobemide, a prototype RIMA | Q28285833 |
| | A review of the pharmacology of selegiline | Q28323156 |
| | Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers | Q34397267 |
| | Depression and Parkinson's disease: a review | Q35313173 |
| | The molecular pharmacology of L-deprenyl | Q36359604 |
| | Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease | Q36972842 |
| | Multiple forms of monoamine oxidase: fact and artefact | Q39109542 |
| | Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs | Q39944094 |
| | Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites | Q40651898 |
| | Clinical pharmacology of reversible monoamine oxidase-A inhibitors | Q40816934 |
| | Cumulative effects of irreversible MAO inhibitors in vivo | Q41606216 |
| | Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. | Q42073490 |
| | Deprenyl is metabolized to methamphetamine and amphetamine in man | Q43247355 |
| | Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. | Q46809055 |
| | Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment | Q48205071 |
| | MAO type B inhibitors as adjunct to L-dopa therapy | Q48251601 |
| | Some observations upon a new inhibitor of monoamine oxidase in brain tissue. | Q51183428 |
| | The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. | Q51272067 |
| | Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. | Q51627274 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 273-8 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline | |
| P478 | volume | 49 | |